New York, NY -- (SBWIRE) -- 12/09/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Generex Biotechnology Corporation (OTCMKTS:GNBT), Monster Worldwide, Inc (NYSE:MWW), Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV), Applied Materials, Inc (NASDAQ:AMAT)
Generex Biotechnology Corporation (OTCMKTS:GNBT) showed a volume of 1.88million shares by the end of last trade whereas the average volume of the stock remained 1.86 million shares. The stock opened the session at $0.03 but then moved to $0.0297. At that price, the stock showed a negative performance of -2.30%. Generex Biotechnology Corporation is a Canada-based Company, which develops drug delivery systems and technologies for the treatment of diabetes. The Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity. Its buccal insulin spray product, Generex Oral-lyn is in Phase III clinical trials at several sites around the world. The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device.
Will GNBT Get Buyers Even After The Recent Rally? Find Out Here
Monster Worldwide, Inc (NYSE:MWW) opened the session at $5.35 and closed the session at $5.38. The stock showed a positive performance of 1.89% in previous trading session. Traded with volume of 3.15 million shares in the prior session and the average volume of the stock remained 2.46 million shares. Monster Worldwide, Inc. (Monster Worldwide) is parent company of Monster, the global online employment solution. With a presence in approximately 55 countries globally, including key markets in North America, Europe, South America and the Asia-Pacific region, Monster offers online recruiting solutions.
For How Long MWW will fight for Profitability? Read This Trend Analysis report
Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) opened the session at $1.56 and closed the session at $1.54. The stock showed a /negative performance of -1.28% in previous trading session. Traded with volume of 417,005.00 shares in the prior session and the average volume of the stock remained 349,760.00 shares. The beta of the stock remained 10.78. InVivo Therapeutics Holdings Corp., formerly Design Source, Inc. is a development-stage company. The Company is developing and commercializing technologies for the treatment of spinal cord injuries. The Company develops biopolymer scaffolding devices for the treatment of spinal cord injuries. The biopolymer devices are designed to protect the damaged spinal cord from further secondary injury and promote neuroplasticity,
Why Should Investors Buy NVIV After the Recent Fall? Just Go Here and Find Out
Applied Materials, Inc (NASDAQ:AMAT) the stock advanced 2.00% and finished the session at $0.0012. Traded with volume of 11.89 million shares in the prior session and the average volume of the stock remained 10.59 million shares. The beta of the stock remained 1.38. Applied Materials, Inc. (Applied) provides manufacturing equipment, services and software to the global semiconductor, flat panel display, solar photovoltaic (PV) and related industries. Applied’s customers include manufacturers of semiconductor wafers and chips, flat panel liquid crystal displays (LCDs), solar PV cells and modules,
Will AMAT Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)